Created by DDW and sponsored by Bio-Rad, The future of antibody-based drugs: Where are the opportunities and what does the future hold? is a free In Focus report, available here. 

This report will:  

• Provide an overview of the monoclonal antibody (mAbs) industry: market value, key on the future of antibody-based drug players, opportunities and the future 
• Explore what’s next for antibody-based drugs and where the opportunity is coming from 
• Include an interview Bio-Rad’s John Cardone, who shares expertise on the future of antibody-based drug discovery  
• Share significant future trends for the therapeutic antibody market 

Key insights:  

• The global mAb market size was valued at $185.50 billion in 2021 
• Biopharmas originating in China will likely have greater influence on the industry by 2028 
• The lessons learned from mAb development for SARS-CoV-2 will likely provide an important platform for the scientific community 
• With over 10 biosimilars approved, Argentina and Brazil have the most biosimilar monoclonal antibodies approved in Latin America
• Of the total number of antibody drugs approved worldwide, 93% were approved first by four drug regulatory agencies: the FDA, EMA, PMDA and NMPA 

Download this report now to learn more.